查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1678664

全球罕見血友病因子市場：市場規模、佔有率、趨勢分析（缺乏因子類型、藥物類別、分銷管道和地區）、細分市場預測（2025-2030 年）

Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Factor Deficiency Type, By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

罕見血友病因素市場的成長與趨勢：

根據 Grand View Research, Inc. 的一份新報告，全球罕見血友病因子市場預計到 2030 年將達到 4.904 億美元，2025 年至 2030 年的複合年成長率為 6.4%。

幾種已獲得美國FDA 等監管機構行銷核准的濃縮因子預計將大幅促進市場成長。此外，越來越多的患者採用預防性治療也有望在未來幾年推動市場成長。對於患有嚴重罕見血友病因素疾病的患者，建議進行預防性治療以避免出血發作並改善生活品質。 COVID-19 疫情對市場成長產生了重大影響。

疫情使得病患安全和感染控制受到更大重視，從而提高了在進行某些凝血因子療法時對安全預防措施的認知和重視。醫療保健提供者和患者在治療過程中更加重視遵守衛生習慣，包括適當的消毒、手部衛生和使用個人防護設備。對病人安全措施的加強重視可能對罕見血友病因素的治療帶來長期益處。儘管疫情帶來了挑戰，但對罕見血友病特異性凝血因子治療的需求仍然很高。患有罕見血友病的人仍然需要這些治療方法來有效地管理和治療他們的病情。

政府推出的優惠措施和提高診斷和治療率的命令正在推動市場成長。例如，1983年，美國國會頒布了《孤兒藥法案》（ODA）。 1983年至2015年，約有3,647種藥物被指定為孤兒藥，554種藥物獲得美國FDA核准。市場參與企業不斷推出創新產品、建立合作夥伴關係並採取其他舉措，以在競爭激烈的市場中佔據優勢。例如，2022年11月，FDA宣布核准一種創新基因療法，用於治療一種遺傳性血液凝固障礙—B型血友病 Kymriah 是一種基於基因的治療方法，用於治療 25 歲及以下患有 B 細胞前體血友病的人。

罕見血友病因子市場：概述

  • 因子 VII 缺乏症將佔據市場主導地位，到 2024 年將佔據 35.1% 的佔有率。預測期內，因子 XIII 缺乏症預計將以 7.1% 的最快複合年成長率成長。
  • 重組療法將引領市場，到 2024 年將佔據 50.3% 的佔有率。預計預防保健在預測期內將實現最快的複合年成長率，為 7.5%。
  • 2024 年，醫院藥局佔最大佔有率，為 59.9%。預計在預測期內，線上藥局的複合年成長率最快，為 9.2%。
  • 2024 年北美罕見血友病因素市場佔據全球市場主導地位，收益佔有率為 38.7%。預計亞太地區罕見血友病因素市場在預測期內將實現最快的複合年成長率，為 6.1%。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

3. 罕見血友病因素市場：促進因素、趨勢和範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTEL 分析

第 4 章 罕見血友病因子市場：依因子缺乏類型進行的商業分析

  • 按要素缺陷類型分類的市場佔有率（2024 年和 2030 年）
  • 因素缺陷類型儀表板
  • 按要素缺陷類型分類的市場規模預測及趨勢分析（2018-2030 年）
  • 第七因子缺乏
  • 因子 XI 缺乏（血友病 C）
  • 因子 XIII 缺乏
  • 其他

5. 罕見血友病因素市場：依藥物類別進行的商業分析

  • 按藥物類別分類的市場佔有率（2024 年和 2030 年）
  • 藥品類別儀表板
  • 依藥物類別分類的市場規模預測及趨勢分析（2018-2030年）
  • 重組療法
  • 血漿衍生療法
  • 預防性治療
  • 其他

6. 罕見血友病因素市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2030 年）
  • 分銷通路儀表板
  • 按分銷管道分類的市場規模預測及趨勢分析（2018-2030 年）
  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 線上藥局市場（2018-2030）

第 7 章：罕見血友病因素市場：按地區分類的估計和趨勢分析

  • 各地區市場佔有率分析（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 按國家/地區分類（2018-2030 年）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類（2018-2030 年）
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 按國家/地區分類（2018-2030 年）
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類（2018-2030 年）
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 按國家/地區分類（2018-2030 年）
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Takeda Pharmaceutical Company Limited
    • Biogen
    • Novo Nordisk A/S
    • Bayer AG
    • CSL
    • Pfizer Inc.
    • Sanofi
    • F. Hoffmann-La Roche Ltd
    • Swedish Orphan Biovitrum AB（publ）
    • Octapharma AG
    • Grifols, SA
    • BioMarin
Product Code: GVR-2-68038-104-7

Rare Hemophilia Factors Market Growth & Trends:

The global rare hemophilia factors market size is expected to reach USD 490.4 million by 2030, registering a CAGR of 6.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Several factor concentrates gaining marketing approvals from regulatory bodies, such as the U.S. FDA, are expected to provide a significant push to the market growth. In addition, the rising adoption of prophylaxis treatment by patients is expected to boost market growth in the coming years. Patients with severe rare hemophilia factor disorders are recommended prophylactic treatment to avoid bleeding episodes and improve quality of life. The COVID-19 pandemic had a significant impact on the market growth.

The pandemic's emphasis on patient safety and infection control measures led to an increased awareness and importance placed on safety measures in the administration of specific clotting factor therapies. Healthcare providers and patients became more conscientious about following hygienic practices during treatment administration, such as proper disinfection, hand hygiene, and the use of personal protective equipment. This increased emphasis on patient safety measures may have long-term benefits for the administration of rare hemophilia factors. Despite the challenges posed by the pandemic, there was still a high demand for specific clotting factor therapies for rare hemophilia. Patients with rare hemophilia types still required these therapies to effectively manage and treat their condition.

Favorable government initiatives and mandates to increase diagnosis and treatment rates are boosting market growth. For instance, the U.S. Congress enacted the Orphan Drug Act (ODA) in 1983. From 1983 to 2015, around 3,647 drugs were designated the status of orphan drugs, and 554 drugs were approved by the U.S. FDA. The market players are constantly undertaking initiatives, such as innovative product launches and collaborations, to gain an advantage in the highly competitive market. For instance, in November 2022, the FDA announced its approval of an innovative gene therapy for the treatment of genetic blood-clotting Hemophilia B disorder. Kymriah, the gene-based therapy, is used for the treatment of B-cell precursor hemophilia patients below 25 years of age.

Rare Hemophilia Factors Market Report Highlights:

  • Factor VII deficiency dominated the market and accounted for a share of 35.1% in 2024. Factor XIII deficiency is expected to grow at the fastest CAGR of 7.1% over the forecast period.
  • Recombinant therapies led the market and accounted for a share of 50.3% in 2024. Prophylactic treatments are expected to register the fastest CAGR of 7.5% over the forecast period.
  • Hospital pharmacies held the largest market share of 59.9% in 2024. Online pharmacies are projected to grow at the fastest CAGR of 9.2% over the forecast period.
  • North America rare hemophilia factors market dominated the global market with a revenue share of 38.7% in 2024. Asia Pacific rare hemophilia factors market is expected to register the fastest CAGR of 6.1% in the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Factor Deficiency Type
    • 1.2.2. Drug Class
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rare Hemophilia Factors Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Rare Hemophilia Factors Market: Factor Deficiency Type Business Analysis

  • 4.1. Factor Deficiency Type Market Share, 2024 & 2030
  • 4.2. Factor Deficiency Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Factor Deficiency Type, 2018 to 2030 (USD Million)
  • 4.4. Factor VII Deficiency
    • 4.4.1. Factor VII Deficiency Market, 2018 - 2030 (USD Million)
  • 4.5. Factor XI Deficiency (Hemophilia C)
    • 4.5.1. Factor XI Deficiency (Hemophilia C) Market, 2018 - 2030 (USD Million)
  • 4.6. Factor XIII Deficiency
    • 4.6.1. Factor XIII Deficiency Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Rare Hemophilia Factors Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Recombinant Therapies
    • 5.4.1. Recombinant Therapies Market, 2018 - 2030 (USD Million)
  • 5.5. Plasma-derived Therapies
    • 5.5.1. Plasma-derived Therapies Market, 2018 - 2030 (USD Million)
  • 5.6. Prophylactic Treatments
    • 5.6.1. Prophylactic Treatments Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Rare Hemophilia Factors Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
  • 6.7. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Rare Hemophilia Factors Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Takeda Pharmaceutical Company Limited
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Biogen
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Novo Nordisk A/S
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bayer AG
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. CSL
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Pfizer Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Sanofi
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. F. Hoffmann-La Roche Ltd
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Swedish Orphan Biovitrum AB (publ)
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Octapharma AG
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Grifols, S.A.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. BioMarin
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global rare hemophilia factors market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 5. Global rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 6. Global rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7. North America rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 9. North America rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 10. North America rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11. U.S. rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 12. U.S. rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 13. U.S. Rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14. Canada rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 15. Canada rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 16. Canada rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Mexico rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 18. Mexico rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 19. Mexico rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Europe rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
  • Table 21. Europe rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 22. Europe rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 23. Europe rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. UK rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 25. UK rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 26. UK Rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27. Germany rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 28. Germany rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 29. Germany rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. France rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 31. France rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 32. France Rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Italy rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 34. Italy rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 35. Italy rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36. Spain rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 37. Spain rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 38. Spain rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39. Norway rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 40. Norway rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 41. Norway Rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Denmark rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 43. Denmark rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 44. Denmark rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Sweden rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 46. Sweden rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 47. Sweden rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48. Asia Pacific rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
  • Table 49. Asia Pacific rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 50. Asia Pacific rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52. Japan rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 53. Japan rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 54. Japan rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55. China rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 56. China rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 57. China rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. India rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 59. India rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 60. India rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Australia rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 62. Australia rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 63. Australia rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64. South Korea rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 65. South Korea rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 66. South Korea rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. Thailand rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 68. Thailand rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 69. Thailand rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70. Latin America rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
  • Table 71. Latin America rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 72. Latin America rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 73. Latin America rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74. Brazil rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 75. Brazil rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 76. Brazil rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77. Argentina rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 78. Argentina rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 79. Argentina rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa Rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84. South Africa rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 85. South Africa rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 86. South Africa rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90. UAE rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 91. UAE rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 92. UAE rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93. Kuwait rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 94. Kuwait rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 95. Kuwait rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Rare hemophilia factors market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Factor deficiency type and drug class outlook (USD Million)
  • Fig. 10 Distribution channel outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Rare hemophilia factors market dynamics
  • Fig. 13 Rare hemophilia factors market: Porter's five forces analysis
  • Fig. 14 Rare hemophilia factors market: PESTLE analysis
  • Fig. 15 Rare hemophilia factors market: Factor deficiency type segment dashboard
  • Fig. 16 Rare hemophilia factors market: Factor deficiency type market share analysis, 2024 & 2030
  • Fig. 17 Factor VII deficiency market, 2018 - 2030 (USD Million)
  • Fig. 18 Factor XI deficiency (Hemophilia C) market, 2018 - 2030 (USD Million)
  • Fig. 19 Factor XIII deficiency market, 2018 - 2030 (USD Million)
  • Fig. 20 Others market, 2018 - 2030 (USD Million)
  • Fig. 21 Rare hemophilia factors market: Drug class segment dashboard
  • Fig. 22 Rare hemophilia factors market: Drug class market share analysis, 2024 & 2030
  • Fig. 23 Recombinant therapies market, 2018 - 2030 (USD Million)
  • Fig. 24 Plasma-derived therapies market, 2018 - 2030 (USD Million)
  • Fig. 25 Prophylactic treatments market, 2018 - 2030 (USD Million)
  • Fig. 26 Others market, 2018 - 2030 (USD Million)
  • Fig. 27 Rare hemophilia factors market: Distribution channel segment dashboard
  • Fig. 28 Rare hemophilia factors market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 29 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 30 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 31 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 32 Rare hemophilia factors market revenue, by region
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. country dynamics
  • Fig. 37 U.S. rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 38 Canada country dynamics
  • Fig. 39 Canada rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico country dynamics
  • Fig. 41 Mexico rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 43 UK country dynamics
  • Fig. 44 UK rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 45 Germany country dynamics
  • Fig. 46 Germany rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 47 France country dynamics
  • Fig. 48 France rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy country dynamics
  • Fig. 50 Italy rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain country dynamics
  • Fig. 52 Spain rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway country dynamics
  • Fig. 54 Norway rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 55 Sweden country dynamics
  • Fig. 56 Sweden rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 57 Denmark country dynamics
  • Fig. 58 Denmark rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 60 Japan country dynamics
  • Fig. 61 Japan rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 62 China country dynamics
  • Fig. 63 China rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 64 India country dynamics
  • Fig. 65 India rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 66 Australia country dynamics
  • Fig. 67 Australia rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 68 South Korea country dynamics
  • Fig. 69 South Korea rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 70 Thailand country dynamics
  • Fig. 71 Thailand rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 72 Latin America rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 73 Brazil country dynamics
  • Fig. 74 Brazil rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 75 Argentina country dynamics
  • Fig. 76 Argentina rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 77 MEA rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 78 South Africa country dynamics
  • Fig. 79 South Africa rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 80 Saudi Arabia country dynamics
  • Fig. 81 Saudi Arabia rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 82 UAE country dynamics
  • Fig. 83 UAE rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 84 Kuwait country dynamics
  • Fig. 85 Kuwait rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 86 Company categorization
  • Fig. 87 Company market position analysis
  • Fig. 88 Strategic framework